Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Insider Sale: Chief Scientific Officer of $AKRO (AKRO) Sells 2,450 Shares

Timothy Rolph, the Chief Scientific Officer of $AKRO ($AKRO), sold 2,450 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.4%...

AKRO : 29.34 (+3.31%)
Insider Sale: Senior VP of $AKRO (AKRO) Sells 925 Shares

Patrick Lamy, the Senior VP of $AKRO ($AKRO), sold 925 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.9% of their shares....

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

AKRO : 29.34 (+3.31%)
Akero Therapeutics Reports Positive Results for Efruxifermin in Treating Metabolic Dysfunction-Associated Steatohepatitis at AASLD Liver Meeting 2024

Over 40% of EFX 50mg participants experienced liver fibrosis regression after 96 weeks, demonstrating significant clinical efficacy.Quiver AI SummaryAkero Therapeutics announced promising results from...

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Present at the Jefferies London Healthcare Conference

AKRO : 29.34 (+3.31%)
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

AKRO : 29.34 (+3.31%)
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug

Sagimet Biosciences’ SGMT stock rose 12.6% on Tuesday after it announced that the FDA has granted breakthrough therapy designation (“BTD”) to its lead pipeline candidate, denifanstat, for treating...

VKTX : 42.25 (+1.83%)
MDGL : 308.44 (+5.12%)
AKRO : 29.34 (+3.31%)
SGMT : 4.95 (-2.37%)
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024

Stocks that traded heavily or had substantial price changes on Monday: Macy’s, United Rentals rise; Apple, Spirit Airlines fall

SMCI : 31.59 (+1.12%)
SAVE : 1.0800 (-18.18%)
BLKB : 76.31 (+0.16%)
URI : 722.64 (+1.65%)
AKRO : 29.34 (+3.31%)
M : 16.24 (+2.46%)
AAPL : 254.49 (+1.88%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar